Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Merck to Acquire Viralytics for $394 Million

Merck & Co. is driving forward in its quest to develop a premier immuno-oncology pipeline with the acquisition of Australia-based Viralytics Ltd. and its oncolytic immunotherapy treatments.

Read More »

PDL BioPharma Gives Up On Acquiring Neos

Nevada-based PDL BioPharma will no longer pursue a proposed acquisition of Neos Therapeutics. PDL made three failed attempts to acquire Texas-based Neos.

Read More »

Roche to buy Flatiron Health for $1.9 billion

Roche Holding will buy the rest of U.S. cancer data company Flatiron Health that the Swiss drugmaker does not already own for $1.9 billion to speed development of cancer medicines.

Read More »

Teva Surges After Warren Buffett’s Berkshire Reports $358 Million Stake

Shares of Teva Pharmaceutical were up following news reports that billionaire investor Warren Buffett took a stake in the company.

Read More »

Charles River Acquires Global CRO

Charles River Laboratories, a contract research organization (CRO) with headquarters in Wilmington, Mass., is buying MPI Research for about $800 million.

Read More »

Allergan’s migraine drug succeeds in key study

Allergan Plc reported better-than-expected fourth-quarter 2017 profit and announced positive data on one of the two migraine treatments it is developing.

Read More »

Seattle Genetics Snaps Up Cascadian in $614 Million Buyout Deal

Bothell, Washington-based Seattle Genetics announced it is buying Seattle-based Cascadian Therapeutics for about $614 million.

Read More »

U.S. judge sentences Novelion’s Aegerion

A federal judge sentenced Aegerion for improperly marketing a cholesterol drug and ordered that some of the $40.1 million it agreed to pay to resolve a U.S. investigation go to the victims.

Read More »

Shire Snaps Up Rights to Preclinical Autoimmune Candidate for Undisclosed Sum

Rare disease giant Shire plc purchased a preclinical autoimmune drug candidate being developed by AB Biosciences.

Read More »

Sanofi Acquires Ablynx for $4.85 Billion

One week after Sanofi agreed to buy Waltham, Mass.-based Bioverativ for $11.6 billion, the French drugmaker announced the acquisition of Ghent, Belgium-based Ablynx for about $4.85 billion.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom